All In Biotech

Drug Trial Radar · NCT07371624

A Study of B2065 in Patients With Acute Ischemic Stroke

A Phase I/IIa Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Allogeneic Adipose-Derived Mesenchymal Stromal Cell Injection (B2065) in Participants With Acute Ischemic Stroke.

Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

54

Planned (sponsor's estimate)

Start

Dec 31, 2025

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Sponsor type
Industry
First posted
Jan 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety of B2065, an allogeneic adipose-derived mesenchymal stromal cell (AD-MSC) injection. It will also assess whether B2065 works to treat acute ischemic stroke. The main questions it aims to answer are: At what dose range is the drug safe for participants? Which dose shows preliminary efficacy? Researchers will compare B2065 to a placebo (a look-alike substance that contains no drug) to see if B2065 works to treat acute ischemic stroke. Participants will: Receive a single dose of B2065 during hospitalization Visit the hospital as scheduled for safety and efficacy assessments

Conditions

  • Acute Ischemic Stroke

Interventions

  • B2065Drug

    Administered by intravenous infusion.

  • PlaceboDrug

    Administered by intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose-Limiting Toxicities (DLTs) [Safety]Time frame: Within 28 days after dosing.
  2. Incidence of Infusion-Related Reactions [Safety]Time frame: Within 7 days, 14 days, and 28 days.
  3. All-Cause Mortality Rate [Safety]Time frame: Within 14 days,12 months, and 24 months.
  4. Incidence of abnormal imaging findings indicative of tumorigenicity [Safety]Time frame: Month 6 and month 24.
  5. Change from baseline in serum tumor marker levels [Safety]Time frame: Change from baseline at Month 6 and Month 24.
  6. Incidence and severity of Treatment-Emergent Adverse Events (TEAEs) [Safety]Time frame: Day1 to month 24 post-dose.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Tiantan Hospital, Capital Medical University

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.